Aurobindo Pharma: Lymphoma trials
The registry lists 10 Lymphoma studies with Aurobindo Pharma as lead sponsor. 0 are open to participants now and 2 have results posted.
Phase 1 7Phase 2 4No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative MalignanciesCompletedNCT00481871Phase 1/2Results posted
- Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell LymphomaCompletedNCT00364923Phase 2Results posted
- A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)CompletedNCT02594267Phase 1
- Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological MalignanciesCompletedNCT02106650Phase 2
- Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHLCompletedNCT01851551Phase 1/2
- Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)CompletedNCT01839097Phase 1
- Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving FolotynWithdrawnNCT01789723Phase 1
- Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell LymphomaCompletedNCT01134341Phase 1
- Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment RegistryCompletedNCT01110733
- Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell LymphomaCompletedNCT00554827Phase 1